Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Michigan for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Michigan only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Michigan (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Richard Zekman (NPI 1043426521)

Field	Value
Entity Type	Individual
Organization	Richard Zekman
Address	3577 W 13 Mile Rd
City	Royal Oak
State	MI
ZIP	48073
Taxonomy	Medical Oncology Physician
NPI Enumerated	May 14, 2007

Payer Source	Total Paid
Medicare	$1.4M
Medicaid	$0

Key Findings

Practice mix is consistent with a medical oncology infusion practice: the provider’s top-revenue items include immunotherapy and bone-modifying agents (J9271, J0897) alongside chemotherapy administration and infusion codes (96413, 96365, 96401, 96417) and multiple supportive-care biologics (Q5108, Q5106). This combination of high-cost oncologic injectables and a range of chemotherapy infusion/add-on codes suggests the operation is focused on in-office systemic cancer therapy and same-day infusion services.

Revenue is concentrated in a small number of Medicare codes: the precomputed top-3 codes (J9271, J0897, 99213) account for 60.0% of this provider’s total Medicare revenue, with J9271 producing $510.4K (37.5%), J0897 $216K (15.8%), and 99213 $90.7K (6.7%). That level of concentration means changes in utilization or reimbursement for any one of these codes could materially affect the provider’s Medicare revenue.

Payer mix is effectively single-payer Medicare: lifetime Medicare revenue is $1.4M while Medicaid revenue is none, indicating no Medicaid billing on file. For contracting or risk-adjustment considerations this provider should be treated as predominantly Medicare-exposed, and initiatives that rely on Medicaid volume would not apply.

Competitive standing for the highest-cost oncology drug is moderate rather than dominant: J9271 (pembrolizumab) generates $510.4K and ranks #990 of 1841 providers (45th percentile; typical, unremarkable volume), so the provider is a routine national participant for this drug rather than a top-volume center. By contrast, use of the pegfilgrastim biosimilar Q5108 is much more concentrated: Q5108 produced $83.2K, ranks #9 of 125 providers (94th percentile; notably above typical national volume), indicating a top-decile position nationally for that biosimilar.

Several codes appear as statistical outliers on Medicare relative to national peers: 99213 (1.3K claims, $90.7K) and 80047 (2K claims, $25.5K) are both labeled as "extreme outlier, far above typical national volume," suggesting exceptionally high ambulatory visit and BMP lab volumes versus peers. Other codes with "notably above typical national volume" designations—such as Q5106 (rank #30 of 695, 10.1K claims, $60.6K) and 96367 (717 claims, $16.5K)—point to above-typical use of certain biosimilars and infusion-related services.

Operational profile shows high-frequency, low-unit-price supportive medications and adjuncts alongside high-cost immunotherapy: examples include J1439 (16.5K claims, $16.5K at $1 avg/claim) and J0640 (1.5K claims, $4.5K), which indicate large claim counts for per-mg or per-unit priced agents and supportive therapy. Coupled with substantial claim counts for Q5106 (10.1K claims) and J0897 (12K claims), this pattern is consistent with routine administration of multi-agent regimens where many small-unit drugs are billed frequently.

Clinical scope spans outpatient and inpatient settings and includes complex evaluations: the provider reports high-volume office E/M visits (99213 with 1.3K claims) alongside hospital-based codes such as 99232 (674 claims) and 99223 (150 claims), and higher-complexity new-patient encounters (99205, 100 claims). This mix indicates the provider delivers care across ambulatory infusion clinics and inpatient/observation settings and performs both routine follow-ups and higher-complexity consultations.

The provider’s NPI tenure (enumerated 2007-05-14, ~19 years ago) indicates a long-established billing presence; paired with the observed code mix and recurring high-claim items, this suggests an experienced practice with established infusion workflows and stable Medicare engagement.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

53 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	11,600	$40	$510.4K
J0897	Injection, denosumab, 1 mg	12,000	$20	$216K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	1,320	$70	$90.7K
Q5108	Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg	880	$100	$83.2K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	2,190	$40	$79K
Q5106	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	10,100	$10	$60.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	450	$100	$45.7K
99232	The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a moderate level of medical decision making or…	670	$60	$43.1K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	340	$80	$26.2K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	270	$100	$25.6K

Showing 1–10 of 53

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 53 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Michigan Distribution

Richard Zekman — 10 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Michigan

Full comparison — all codes billed, vs. state median

53 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	9	30	8,800	$40	$473.6K
J1569	8	10	4,550	$40	$197.2K
J0897	7	170	2,460	$20	$69.1K
Q5108	1	10	310	$100	$39.1K
J2506	6	10	340	$80	$27.8K
J1439	20	30	21,750	$1	$20.3K
Q5106	3	20	1,300	$10	$18.8K
96413	9	170	120	$100	$16.1K
Q0138	5	40	29,070	$1	$12.8K
99232	368	6,730	90	$60	$12K

Showing 1–10 of 53

Related Providers

Other providers that share a Tax Identification Number (TIN) with Richard Zekman, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Michigan Healthcare Professionals PC	MI	Internal Medicine Physician	$0	$106.2M
Oakwood Ambulatory LLC	MI	Internal Medicine Physician	$0	$66.9M
Columbus Radiology Corp	OH	Diagnostic Radiology Physician	$0	$49.9M
Somc Medical Care Foundation, Inc.	OH	Family Medicine Physician	$0	$25.3M
Sandeep Randhawa	MI	Retina Specialist (Ophthalmology) Physician	$7M	$0
Jeremy Wolfe	MI	Retina Specialist (Ophthalmology) Physician	$3.7M	$0
Christianne Wa	CA	Retina Specialist (Ophthalmology) Physician	$3.5M	$0
Jeffrey Margolis	MI	Hematology & Oncology Physician	$3M	$0
Faisal Musa	MI	Hematology & Oncology Physician	$3M	$0
Tamer Mahmoud	MI	Retina Specialist (Ophthalmology) Physician	$2.8M	$0

Nearby Providers

Other providers in the same ZIP code as Richard Zekman, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
William Beaumont Hospital	MI	Hospitalist Physician	$0	$167.9M
William Beaumont Hospital	MI	General Acute Care Hospital	$0	$162.4M
Judson Center, Inc.	MI	Community/Behavioral Health Agency	$0	$21.2M
Associated Retinal Consultants, PC	MI	Ophthalmology Physician	$0	$21.1M
Allergy & Asthma Associates Of Mi PC	MI	Allergy & Immunology Physician	$0	$15.9M
Community Homes, Inc.	MI	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$7.5M
American Anesthesiology Of Michigan PC	MI	Anesthesiology Physician	$0	$5.7M
Joshua Robinson	MI	Ophthalmology Physician	$3.7M	$0
George Williams	MI	Retina Specialist (Ophthalmology) Physician	$2.7M	$0
Kimberly Drenser	MI	Retina Specialist (Ophthalmology) Physician	$2.7M	$0

Richard Zekman — Billing Profile & Reimbursement Data

Sign up for Richard Zekman — Billing Profile & Reimbursement Data policy alerts

Richard Zekman — Billing Profile & Reimbursement Data

Sign up for Richard Zekman — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References